BIOMILQ, Inc.’s $21 Million Series A Financing

Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the deal.

North Carolina-based mammary biotechnology company BIOMILQ, Inc., announced the successful close of $21 million in Series A financing, which will enable their acceleration of bringing cell-cultured human milk to market. Leading the fundraise are Danish life science investor Novo Holdings and clean tech leader Breakthrough Energy Ventures. Additional support comes from Blue Horizon, Spero Ventures, Digitalis Ventures, Green Generation Fund, Alexandria and Gaingels.

Investment partners for the round were selected based in part on alignment with BIOMILQ’s core set of values: having female leadership within their fund, having a portfolio of diverse founders, and having an internal mandate for positive impact in the world. Utilizing proprietary technology, BIOMILQ announced capability for producing human milk outside of the body this year. The additional funds from the fundraise will accelerate their process development and optimization, enabling full commercialization over the next 4 years.

The Wilson Sonsini team that represented Novo Holdings on the transaction included: Dan Koeppen (Picture), Kassandra Castillo, Bridget Balisy, Mike Hostetler, Deborah Smith, Stephanie Dusaban Gonzales, Stephen Heifetz and Jonathan Davey.

Involved fees earner: Bridget Balisy – Wilson Sonsini Goodrich & Rosati; Kassandra Castillo – Wilson Sonsini Goodrich & Rosati; Jonathan Davey – Wilson Sonsini Goodrich & Rosati; Stephanie Dusaban Gonzales – Wilson Sonsini Goodrich & Rosati; Stephen Heifetz – Wilson Sonsini Goodrich & Rosati; Michael Hostetler – Wilson Sonsini Goodrich & Rosati; Dan Koeppen – Wilson Sonsini Goodrich & Rosati; Deborah Smith – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: Novo Holdings A/S;

Author: Martina Bellini